Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 18, 2016 07:45 ET | Source: Arch Biopartners Inc.

Arch Biopartners Forms Clinical and Medical Advisory Board for AB569

TORONTO, ONTARIO--(Marketwired - July 18, 2016) - Arch Biopartners, Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) today announced the formation of a clinical and medical...
July 05, 2016 08:00 ET | Source: Arch Biopartners Inc.

Arch "Borg" Peptide Coating Displays Anti Corrosion Performance on Stainless Steel

TORONTO, ONTARIO--(Marketwired - July 5, 2016) - Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) today announced that scientists at a corrosion research...
June 23, 2016 07:30 ET | Source: Arch Biopartners Inc.

Arch Biopartners Closes First Tranche of Private Placement

TORONTO, ONTARIO--(Marketwired - June 23, 2016) - Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today it has raised $330,000 by closing the first...
June 14, 2016 09:13 ET | Source: Arch Biopartners Inc.

Arch Biopartners Announces Non Brokered Private Placement Financing

TORONTO, ONTARIO--(Marketwired - June 14, 2016) - Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) a portfolio based biotechnology company, intends to...
June 01, 2016 15:28 ET | Source: Arch Biopartners Inc.

Arch Biopartners' AB569 Receives Final Approval from European Commission for Orphan Designation for Cystic Fibrosis

TORONTO, ONTARIO--(Marketwired - June 1, 2016) - Arch Biopartners Inc. (Arch, or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), a portfolio based biotechnology company, today announced...
April 26, 2016 08:33 ET | Source: Arch Biopartners Inc.

Arch Biopartners' AB569 Receives Positive Opinion from EMA COMP for Orphan Designation for Cystic Fibrosis

TORONTO, ONTARIO--(Marketwired - April 26, 2016) - Arch Biopartners Inc. (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), a portfolio based biotechnology company, today...
March 16, 2016 03:00 ET | Source: Arch Biopartners Inc.

Arch Biopartners Enters Exclusive License Agreement With University of Cincinnati for AB569

TORONTO, ONTARIO--(Marketwired - March 16, 2016) - Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today it has entered into an exclusive license...
March 01, 2016 07:45 ET | Source: Arch Biopartners Inc.

Arch Scientists Publish Data on the Efficacy and Mechanism of Action of Lead Drug Candidate AB569

TORONTO, ONTARIO--(Marketwired - March 1, 2016) - Arch Biopartners Inc (Arch) or (the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF) announced today that Dr. Daniel Hassett's team at the...
February 03, 2016 09:00 ET | Source: Arch Biopartners Inc.

Arch Biopartners Submits Orphan Drug Application for AB569 to European Medicines Agency

TORONTO, ONTARIO--(Marketwired - Feb. 3, 2016) - Arch Biopartners Inc. (Arch, or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), a portfolio based biotechnology company, today announced they have...
January 06, 2016 12:12 ET | Source: Arch Biopartners Inc.

Arch Biopartners, McMaster Scientists, Expand MetaMx Collaboration with Mitacs Award

TORONTO, ONTARIO--(Marketwired - Jan. 6, 2016) - Arch Biopartners Inc., (Arch or the Company) (TSX VENTURE:ACH)(OTCBB:FOIFF), a portfolio based biotechnology company, today announced a...